SubjectWell Welcomes Matthias Roos as New Director of Scientific Affairs

SubjectWell, a leader in the transformation of patient recruitment in clinical development, has recently announced the appointment of Matthias Roos as its new Director of Scientific Affairs. This strategic move aims to bolster the company’s mission to address the key challenges faced in clinical research today. Roos's extensive background in clinical trial technology, paired with his strategic leadership skills, positions him excellently to lead significant research initiatives and foster thought leadership programs that can stimulate change among sponsors, clinical research organizations (CROs), and clinical sites.

In making the announcement, Fred Martin, CEO of SubjectWell, expressed excitement about the new addition to the team, emphasizing that Roos's comprehensive understanding of the scientific, business, clinical, and regulatory aspects of the industry is critical. This expertise is expected to strengthen SubjectWell’s capabilities in transforming the approach to clinical development, enhancing patient recruitment, and improving overall patient experiences.

Matthias Roos arrives at SubjectWell with a wealth of experience. Prior to joining, he served as the Director of Strategy at Climedo, where he played a pivotal role in driving launch excellence as well as developing agile solutions tailored for Real-World Evidence (RWE) and non-interventional prospective studies (NIS). His background also includes working as a Senior Consultant for McKinsey & Company, where he advised a diverse range of clients in the pharmaceutical, automotive, engineering, and enterprise technology sectors on corporate strategy, operations, and research and development (R&D).

His academic credentials are impressive, holding a Ph.D. in Physics from the Martin Luther University of Halle-Wittenberg. Roos expanded his research credentials as a Postdoctoral Research Fellow at the Massachusetts Institute of Technology (MIT), contributing to the scientific community with five peer-reviewed publications. His accolades include the Ernst Award from the German Chemical Society in 2017 and a postdoctoral fellowship from the German National Academy of Sciences Leopoldina. Over his career, Roos has authored 15 scientific papers which have collectively garnered over 600 citations, showcasing his significant contributions to the field.

SubjectWell, the company Roos joins, has revolutionized the patient recruitment landscape by creating a robust technology platform that is both comprehensive and patient-centric. Their patient network boasts over 13 million patients, along with a cadre of clinically trained, multilingual patient and site companions. This extensive reach enables SubjectWell to launch effective recruiting capabilities across 102 countries, providing critical support to sponsors and CROs. Moreover, their innovative digital media network and services are designed to alleviate site burdens, ultimately enhancing the patient experience, which is essential to the company’s mission.

In summary, Matthias Roos’s arrival at SubjectWell marks a significant step in the company’s commitment to refining clinical development processes and improving patient recruitment efforts. With his strong background and dedication to the field, the future looks bright for both SubjectWell and the broader clinical development community as they seek to innovate and improve methodologies that directly affect patient care and recruitment. SubjectWell looks forward to leveraging Roos's expertise to spearhead initiatives that not only address current challenges but also set new standards in patient-centric research and recruitment practices.